ClinicalTrials.gg
TerminatedNCT04532749Updated Jun 4, 2025Results posted

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

A Phase 3 interventional study of Seltorexant and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Terminated at 80 sites in 10 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
42847922MDD3002 was stopped based on the interim analysis (IA) results as recommended by the Independent Data Monitoring Committee (IDMC)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Enrollment
6th of 12
212 · median 176
Started
2020
with 3 others
Phase 3
5 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
11 of 12
Janssen Research & Development, LLC

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 4 that started in 2020, is one of 5 in phase 3, and was the 9th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Read the detailed description

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that adjunctive treatment with seltorexant is superior to placebo in treating depressive symptoms, as measured by change in Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to Day 43 in adult and elderly participants with MDDIS who have had an inadequate response to treatment with a SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (43 days), and a post treatment follow-up phase (7 to 14 days after DB treatment phase). Total duration of study is up to 12 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet -5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The duration of the current depressive episode must be less than or equal to (\<=) 24 months
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (\<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms other than insomnia present, and overall good tolerability, as assessed by the MGH-ATRQ
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a improvement (that is [ie], an improvement of > 20 % on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >= 18 at the second screening interview
  • Have a patient version of the Insomnia Severity Index (ISI) total score >=15 as well as a clinician version of the ISI total score >=15 at the second screening visit
  • (BMI) between 18 and 40 kilogram per meter square (kg/m\^2) inclusive (BMI=weight/height\^2)
  • Participant must be medically stable on the basis of clinical laboratory tests performed at screening
  • Participant must be medically stable on the basis of the following: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead (ECG) performed at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency ( [CrCl] \< 30 milliliter per minute [mL/min]); or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has clinically significant hepatic disease as defined by >=2* (ULN) increase of (AST) or alanine aminotransferase (ALT) at screening
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (\< 25% improvement in symptoms) when treated with an antidepressant of adequate dose (per massachusetts general hospital-antidepressant treatment response questionnaire [MGH-ATRQ]) and duration (at least 6 weeks).
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, or somatoform disorders
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to criteria within 6 months before screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    Seltorexant

    Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).

    Drug: Seltorexant

  • Placebo comparator
    Placebo

    Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).

    Drug: Placebo

Interventions

  • Participants will receive Seltorexant tablets.

  • DrugPlacebo

    Participants will receive matching placebo tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

    Time frame: Baseline (Day 1), Day 43

Secondary outcomes

  1. Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score

    The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). Higher scores represented a more severe condition. MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

    Time frame: Baseline (Day 1), Day 43

  2. Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score

    PROMIS-SD Short Form 8a: static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has 5 options ranged 1 to 5. The "direction" of responses was not same, sometimes "not at all" =more sleep disturbance; sometimes "not at all" =less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores=less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean-50; SD-10. Negative changes in scores=improvement. Higher PROMIS T-score represents more concept measured. Negatively worded (like sleep disturbance), T-score of 60 was one SD worse than average. By comparison, T-score of 40 was one SD better than average. T-score of 50 or above was clinically significant level of sleep disturbance.

    Time frame: Baseline (Day 1), Day 43

  3. Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score

    The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative changes in MADRS-6 total score indicate improvement.

    Time frame: Baseline (Day 1), Day 43

  4. Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43

    Percentage of participants who achieved response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

    Time frame: At Day 43

  5. Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score

    The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 was categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.

    Time frame: Baseline (Day 1), Day 43

07

Results

Posted Jun 4, 2025

Participant flow

DB Treatment Phase (Day 1 to Day 43)
Participant flow — DB Treatment Phase (Day 1 to Day 43)
MilestoneSeltorexantPlacebo
Started107105
Completed10189
Not completed616
Withdrew: Adverse event16
Withdrew: Lack of efficacy25
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Study terminated by sponsor01
Withdrew: Other12
Follow-up Phase (Day 44 to Day 57)
Participant flow — Follow-up Phase (Day 44 to Day 57)
MilestoneSeltorexantPlacebo
Started10398
Completed10292
Not completed16
Withdrew: Withdrawal by subject03
Withdrew: Adverse event01
Withdrew: Other12

Outcome measures

PrimaryChange From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Units on a scaleSeltorexantPlacebo
Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-14.0 ± 10.46-13.1 ± 9.51
Statistical analysis
  • Seltorexant vs Placebo · Mixed Model Repeated Measures (MMRM) · p = =0.411 · Least square (ls) mean difference: -1.2 · 95% CI -4.00 to 1.64
SecondaryChange From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). Higher scores represented a more severe condition. MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Units on a scaleSeltorexantPlacebo
Change From Baseline to Day 43 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score-12.0 ± 9.27-11.3 ± 8.44
Statistical analysis
  • Seltorexant vs Placebo · MMRM model · p = =0.473 · Ls mean difference: -0.9 · 95% CI -3.41 to 1.59
SecondaryChange From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score

PROMIS-SD Short Form 8a: static 8-item questionnaire, assessed self-perceptions of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items), worrying about sleep (1 item). Each question has 5 options ranged 1 to 5. The "direction" of responses was not same, sometimes "not at all" =more sleep disturbance; sometimes "not at all" =less sleep disturbance. Total raw score for short form with all questions answered was sum of values of response to each question, total score ranged 8 to 40. Lower scores=less sleep disturbance. Total raw score converted into T-score. T-score rescaled the raw score into standardized score with mean-50; SD-10. Negative changes in scores=improvement. Higher PROMIS T-score represents more concept measured. Negatively worded (like sleep disturbance), T-score of 60 was one SD worse than average. By comparison, T-score of 40 was one SD better than average. T-score of 50 or above was clinically significant level of sleep disturbance.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · T-score
Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score
T-scoreSeltorexantPlacebo
Change From Baseline to Day 43 in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD; Short Form 8a) T-score-13.7 ± 11.06-11.9 ± 11.83
Statistical analysis
  • Seltorexant vs Placebo · MMRM Model · p = =0.167 · Ls mean difference: -2 · 95% CI -4.87 to 0.85
SecondaryChange From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score

The 6-item MADRS was a clinician-administered scale designed to measure the core symptoms of depression severity and detected changes due to antidepressant intervention. It is a subset of MADRS (10-item). The MADRS-6 subscale score was the sum of scores for the following MADRS items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranges from 0 to 36, higher scores represented a more severe condition. Negative changes in MADRS-6 total score indicate improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score
Units on a scaleSeltorexantPlacebo
Change From Baseline to Day 43 in the 6-item MADRS (MADRS-6) Total Score-9.1 ± 6.86-8.1 ± 6.37
SecondaryPercentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43

Percentage of participants who achieved response on depressive symptoms scale based on MADRS total score at Day 43 were reported. Responders were defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. The scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Time frame:
At Day 43
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 43
Percentage of participantsSeltorexantPlacebo
Percentage of Participants Who Achieved Response on Depressive Symptoms Scale Based on MADRS Total Score at Day 4342.936.3
SecondaryChange From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score

The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 was categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement.

Time frame:
Baseline (Day 1), Day 43
Reported as:
Mean · Units on a scale
Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score
Units on a scaleSeltorexantPlacebo
Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score-8.8 ± 6.44-8.1 ± 6.27

Adverse events

Collected over Double-blind (DB) Phase: From Day 1 up to Day 43; Follow up Phase: From Day 44 to Day 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Phase: Seltorexant0/107 (0%)0/107 (0%)14/107 (13.1%)
DB Phase: Placebo0/105 (0%)2/105 (1.9%)11/105 (10.5%)
Follow-up Phase: Seltorexant0/103 (0%)0/103 (0%)0/103 (0%)
Follow-up Phase: Placebo0/98 (0%)0/98 (0%)0/98 (0%)
Most frequent serious events
Most frequent serious events
EventDB Phase: SeltorexantDB Phase: PlaceboFollow-up Phase: SeltorexantFollow-up Phase: Placebo
DepressionPsychiatric disorders0/1071/1050/1030/98
AsthmaRespiratory, thoracic and mediastinal disorders0/1071/1050/1030/98
Most frequent other events
Most frequent other events
EventDB Phase: SeltorexantDB Phase: PlaceboFollow-up Phase: SeltorexantFollow-up Phase: Placebo
HeadacheNervous system disorders14/10711/1050/1030/98

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SeltorexantPlaceboTotal
Mean50.2 ± 13.8748.8 ± 14.4049.5 ± 14.12
Sex: Female, Male
Sex: Female, Male(Participants)SeltorexantPlaceboTotal
Female7883161
Male292251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SeltorexantPlaceboTotal
Hispanic or Latino383371
Not Hispanic or Latino6872140
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SeltorexantPlaceboTotal
American Indian or Alaska Native000
Asian549
Native Hawaiian or Other Pacific Islander000
Black or African American91423
White9087177
More than one race000
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(Participants)SeltorexantPlaceboTotal
Argentina131427
Chile347
Denmark112
Finland10919
Malaysia101
Poland6410
Slovakia9817
Korea, South347
Ukraine232548
United States383674
08

Study locations

80 sites
  • Altea Research Institute
    Phoenix, Arizona 85012, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Behavioral Research Specialists LLC
    Glendale, California 91206, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Alliance for Research
    Long Beach, California 90807, United States
  • Excell Research Inc
    Oceanside, California 92056, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • Pharmax Research Clinic Inc
    Miami, Florida 33126, United States
  • Innova Clinical Trials
    Miami, Florida 33133, United States
  • Harmony Clinical Research Inc
    North Miami Beach, Florida 33162, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Synexus Research Orlando
    Orlando, Florida 32806, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Compass Research LLC-Bioclinica Research
    The Villages, Florida 32162, United States
  • Synexus Clinical Research US Inc
    Atlanta, Georgia 30328, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Uptown Research Institute, LLC
    Chicago, Illinois 60640, United States
  • Phoenix Medical Research, Inc.
    Prairie Village, Kansas 66206, United States
  • Michigan Clinical Research Institute
    Ann Arbor, Michigan 48108, United States
  • Eastside Comprehensive Medical Services
    New York, New York 10128, United States
  • Community Research Management Associates, Inc.
    Cincinnati, Ohio 45212, United States
  • Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73106, United States
  • InSite Clinical Research LLC
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • Clínica Privada Banfield S.A
    Banfield, B1828CKR, Argentina
  • STAT Research S A
    Ciudad Autonoma de Buenos Aires, C1013AAB, Argentina
  • NOVAIN Neurociencias Group
    Ciudad Autonoma de Buenos Aires, C10154ABQ, Argentina
  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
    Ciudad Autonoma de Buenos Aires, C1425AHQ, Argentina
  • CEN Consultorios Especializados en Neurociencias
    Cordoba, 5000FJF, Argentina
  • Instituto Medico DAMIC
    Cordoba, X5003DCE, Argentina
  • Sanatorio Prof. Leon S. Morra
    Cordoba, X5009BIN, Argentina
  • INSA Instituto de Neurociencias San Agustín
    La Plata, 1900, Argentina
  • C I A P Centro de investigacion y Asistencia en Psiquiatria
    Rosario, 2000, Argentina
  • Clinica Mayo de UMCB
    San Miguel de Tucuman, T4000IHE, Argentina
  • Psicomed Estudios Medicos
    Antofagasta, 1270244, Chile
  • BioMedica Research Group
    Santiago, 7500710, Chile
  • CeCim - Centro de Estudios Clinicos e Investigacion Medica
    Santiago, 8320000, Chile
  • Hospital Dr Hernan Henriquez Aravena
    Temuco, 47811-51, Chile
  • Psykiatrisk Center Nordsjaelland
    Hillerod, 3400, Denmark
  • Ålborg Universitetshospital
    Ålborg, 9000, Denmark
  • Eira Hospital
    Helsinki, 150, Finland
  • Mederon LTD at ARTES
    Helsinki, 270, Finland
  • Savon Psykiatripalvelu
    Kuopio, 70110, Finland
  • Oulu Mentalcare Oy
    Oulu, 90100, Finland
  • Satakunnan Psykiatripalvelu
    Rauma, 26100, Finland
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, Korea, Republic of
  • Korea University Ansan Hospital
    Gyeonggi-do, 15355, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, 06973, Korea, Republic of
  • Eulji General Hospital
    Seoul, 1830, Korea, Republic of
  • Sunway Medical Centre
    Bandar Sunway, 47500, Malaysia
  • Hospital Kuala Lumpur
    Jalan Pahang, 50586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Hospital Sibu
    Sibu, 96001, Malaysia
  • Podlaskie Centrum Psychogeriatrii
    Bialystok, 15-756, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Czestochowie
    Czestochowa, 42-202, Poland
  • Synexus Polska Sp z o o Oddzial w Katowicach
    Katowice, 40 040, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
    Leszno, 64-100, Poland
  • Synexus Polska Sp z o o
    Lodz, 90 127, Poland
  • Centrum Medyczne Luxmed Sp z o o
    Lublin, 20 109, Poland
  • Psychiatricka Ambulancia Mentum S.R.O.
    Bratislava, 82007, Slovakia
  • Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O.
    Svidník, 089 01, Slovakia
  • Crystal Comfort s.r.o.
    Vranov nad Toplou, 9301, Slovakia
  • BONA MEDIC, s.r.o.
    Zlate Moravce, 95301, Slovakia
  • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
    Kharkiv, 61068, Ukraine
  • CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council
    Kherson, 73488, Ukraine
  • Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa)
    Kyiv, 02192, Ukraine
  • Main Military Clinical Hospital of MDU
    Kyiv, 1133, Ukraine
  • Kyiv Clinical Railway Hospital #2 of the Branch Health Care Center of the PJSC Ukrainian Railway
    Kyiv, 3049, Ukraine
  • CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'
    Lviv, 79021, Ukraine
  • CI Odesa Regional Medical Center of Mental Health
    Odesa, 65014, Ukraine
  • CNCE Odesa regional psychiatric hospital #2 Odesa regional council
    Oleksandrivka, 67513, Ukraine
  • Poltava O.F. Maltsev RC Psychiatric Hospital Dept #9 (Ad-P Dept) HSEIU Ukrainian MSA
    Poltava, 36006, Ukraine
  • CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'
    Smila, 20708, Ukraine
  • CI O.I. Yuschenko VRPsH Depts #7 & #10 M.I. Pyrogov VNMU
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in May 2022, 20 months.

Results were first posted in Jun 2025, 3 years after primary completion. A results delay was requested in May 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Aug 31, 2020
StartActual
Sep 15, 2020
Primary completionActual
May 24, 2022
CompletionActual
Jul 14, 2022
Results delay requested
May 21, 2023
Results first posted
Jun 4, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04532749
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Sep 15, 2020
Primary completion
May 24, 2022
Completion
Jul 14, 2022
Results posted
Jun 4, 2025
Last update
Jun 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion